Abstract：
BACKGROUND: BRAF mutation involved 2-4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations.
METHODS: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients.
RESULTS: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype.
CONCLUSIONS: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.
METHODS: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients.
RESULTS: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype.
CONCLUSIONS: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC.
摘要：
背景：BRAF突变涉及2-4%的肺腺癌。V600E和非V600EBRAF突变NSCLC的临床病理特征和患者预后存在差异。因此，我们试图评估BRAF突变在晚期NSCLC真实人群中的频率和临床相关性,调查不同遗传改变的潜在预后意义。
方法：本意大利多中心回顾性研究涉及晚期BRAF突变型NSCLC。评估BRAFV600E和非V600E患者的完整临床病理数据。
结果：共纳入44例BRAFmutNSCLC患者（V600E，n=23；非V600E，n=21)。生存结果和治疗反应无显著差异，根据V600Evs.非V600E突变，尽管在V600E亚组中观察到了延长PFS的趋势(中位PFS=11.3vs.非V600E的6.0个月）。在总人口中,ECOGPS和年龄对操作系统有显著影响，而骨病变与较短的PFS有关。与免疫疗法相比，一线化疗与总体人群的OS延长相关,尤其是在BRAFV600E亚型中。
结论：这里，我们报告了有BRAF改变的晚期NSCLC回顾性队列的真实数据.我们的研究提供了生存结果的相关线索，治疗反应，与BRAF突变型NSCLC的临床病理相关性。
方法：本意大利多中心回顾性研究涉及晚期BRAF突变型NSCLC。评估BRAFV600E和非V600E患者的完整临床病理数据。
结果：共纳入44例BRAFmutNSCLC患者（V600E，n=23；非V600E，n=21)。生存结果和治疗反应无显著差异，根据V600Evs.非V600E突变，尽管在V600E亚组中观察到了延长PFS的趋势(中位PFS=11.3vs.非V600E的6.0个月）。在总人口中,ECOGPS和年龄对操作系统有显著影响，而骨病变与较短的PFS有关。与免疫疗法相比，一线化疗与总体人群的OS延长相关,尤其是在BRAFV600E亚型中。
结论：这里，我们报告了有BRAF改变的晚期NSCLC回顾性队列的真实数据.我们的研究提供了生存结果的相关线索，治疗反应，与BRAF突变型NSCLC的临床病理相关性。
